Roswell Park Ventures

Roswell Park Ventures is a specialized oncology fund affiliated with the Roswell Park Comprehensive Cancer Center in Buffalo. It provides seed capital to companies commercializing proprietary cancer therapies, with sub-vertical focus on biotech and pharma therapeutics. AI is not a declared focus area, and the thesis is concentrated on translational oncology.

The fund invests at pre-seed and seed with checks of $250K to $1M, consistent with its role as an early commercialization vehicle rather than a growth-stage investor. The natural geographic fit is U.S. companies, with particular relevance to spinouts of Roswell Park research or external programs that can collaborate with the cancer center.

Founders likely to fit are faculty entrepreneurs, licensees, or external oncology startups seeking translational partnership. Expect diligence to span scientific rigor, IP, and feasibility of advancing toward clinical milestones. Engagement typically begins through Roswell Park’s research and tech transfer ecosystem rather than purely external venture channels. Limited public information is available on portfolio scope, so warm introductions are likely the most reliable path in.